Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

WuXi Biologics Starts Building Chengdu Manufacturing Plant, its 12th Globally

publication date: May 16, 2019

WuXi Biologics, a China biologics CRO/CMO, has begun construction of a new 1.3 million square foot integrated manufacturing center for innovative biologics in Chengdu, one of the largest cities in Southwest China. The facility will be WuXi Biologics' 12th drug substance manufacturing facility. Bu 2022, WuXi plans to have a total production capacity of 220,000 liters, with facilities around the world, including China, Ireland, Singapore and US. Initially, the Changdu facility will have a bioreactor capacity of 48,000 liters. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China